Click here to learn how you can leverage WCG's Placebo Response Reduction training for your clinical trial.
Want to read the abbreviated version of the poster? Click on this link to discover more.
Most Recent Flipbooks
Using PANSS Score Profiles to Predict Early Termination in a Study on Acute Exacerbation of Schizophrenia
Blinded analyses were aimed to determine how different atypical Positive and Negative Syndrome Scale (PANSS) score profiles (identified using algorithms) were able to predict early termination.
Using scoring algorithms to identify serious scoring violations among placebo responders and non-responders in clinical trials using the Pos
The objective was to use a priori scoring algorithm designed to assess violations and non-violations on PANSS items.
Validation of Goal Attainment Scaling for Depression: Initial Findings From an Open-Label Study in Patients Switching to Vortioxetine
Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials
Identifying Elevated Rates of CDR Scoring Errors
The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.
Increased Signal Detection in Alzheimer's Disease Clinical Trials
This study investigated the impact of lag time on error rates for commonly used Alzheimer’s disease COAs, as well as the degree to which administration attenuated error rates associated with lag time.
RBANS as a Useful Outcome Measure in Prodromal AD Trials
The goal of the present study was to examine the potential utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in prodromal AD trials.